Prot #QRK207: A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/5/16 → 5/5/22

Funding

  • Parexel ((OE) Prot #QRK207 // (OE) Prot #QRK207)
  • Quark Pharmaceuticals, Inc. ((OE) Prot #QRK207 // (OE) Prot #QRK207)